PD-L1 in ovarian cancer
1 EU-approved indication in ovarian cancer needs a PD-L1 result: pembrolizumab (2nd line, advanced).
Line of therapy
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| PD-L11 | ||||
Keytruda | CPS ≥ 1 | + paclitaxel, with or without bevacizumab | 2L advanced | After one or two prior systemic treatment regimens; platinum-resistant |
8 approvals for Ovarian need no biomarker and apply whatever the result. All approvals for Ovarian
See also
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Pembrolizumab (Keytruda)
KEYTRUDA, in combination with paclitaxel, with or without bevacizumab, is indicated for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1 and who have received one or two prior systemic treatment regimens.